BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Evotec OAI (Germany) (EVTG.F) Sells Single Molecule Detection Technology & IP Portfolio To Olympus Corporation (OCPNF)


7/24/2006 11:59:10 AM

HAMBURG, Germany, July 24 /PRNewswire-FirstCall/ -- Evotec AG today announced that its Tools and Technologies Division (Evotec Technologies GmbH) has sold the core of its Single Molecule Detection Technology and transferred or licensed the corresponding IP portfolio to Olympus Corporation, Tokyo, Japan. This transaction is a further step taken by Evotec Technologies to increasingly focus its business on providing cutting edge cell imaging and cell handling systems for the cell biology growth market.

Over the past years Evotec Technologies has developed a set of innovative confocal detection methods for single molecule drug discovery. This Technology & IP portfolio and the related know-how will now be licensed or transferred to Olympus. Evotec Technologies will continue to market devices based on this IP portfolio and on supplies from Olympus as elements of its drug discovery solutions (i.e. screening systems) and will continue to serve and support the entire existing customer base. However, certain revenues previously planned in 2006 will be transferred to Olympus. Adjusted for the sale of this part of its business which generated approximately EUR 2.5 million revenues with products and services in 2005, Evotec continues to anticipate 0 to 5 % revenue growth in 2006 on its remaining business. The net proceeds from this transaction have already been included in Evotec's latest cash guidance.

The transaction will intensify the long-standing collaboration between Evotec Technologies and Olympus. This collaboration had led to the MF20 molecular interaction analytical system, which is manufactured and marketed by Olympus. Olympus meanwhile has successfully launched the MF20 in Japan.

Both companies will closely work together to best exploit single molecule detection for cellular applications and to ensure the compatibility of Olympus' single molecule detection products with Evotec Technologies' cell biology systems.

"Evotec Technologies is delighted to intensify the long-standing collaboration with Olympus. We are convinced that Olympus is best positioned to successfully market our single molecule technologies to an even broader customer base," said Prof Carsten Claussen, CEO of Evotec Technologies. "At the same time the transaction allows Evotec Technologies to increase the focus of its own business on providing comprehensive solutions for automated cell biology. This strategy has already proven to be successful considering strong sales e.g. with our Opera(TM) analyser, both as a stand-alone system or integrated into a broader automated platform."

"Over the past years we have successfully marketed the MF10 and MF20 readers in Japan which have been jointly developed with Evotec Technologies. With the transaction announced today we are now in a position to build on this success and further broaden our drug discovery business," said Mr. Kazuhisa Yanagisawa, group president of Life Science Group, Olympus Corporation, Tokyo, Japan. "We are looking forward to the close collaboration with our long-lasting technology partner Evotec Technologies."

Contact: Evotec AG Anne Hennecke Director, Investor Relations & Corporate Communications Phone: +49-40-56081-286 Fax: +49-40-56081-333 E-Mail: anne.hennecke@evotec.com

Evotec AG

CONTACT: Contact: Evotec AG, Anne Hennecke, Director, Investor Relations &Corporate Communications, Phone: +49-40-56081-286, Fax: +49-40-56081-333,E-Mail: anne.hennecke@evotec.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES